Cargando…

Elevated markers of thrombo-inflammatory activation predict outcome in patients with cardiovascular comorbidities and COVID-19 disease: insights from the LEOSS registry

AIMS: SARS-CoV-2 infection is associated with adverse outcomes in patients with cardiovascular disease. Here, we analyzed whether specific biomarkers predict the clinical course of COVID-19 in patients with cardiovascular comorbidities. METHODS AND RESULTS: We enrolled 2147 patients with SARS-CoV-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Cremer, Sebastian, Jakob, Carolin, Berkowitsch, Alexander, Borgmann, Stefan, Pilgram, Lisa, Tometten, Lukas, Classen, Annika, Wille, Kai, Weidlich, Simon, Gruener, Beate, Dimmeler, Stefanie, Massberg, Steffen, Rieg, Siegbert, Zeiher, Andreas M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674577/
https://www.ncbi.nlm.nih.gov/pubmed/33211155
http://dx.doi.org/10.1007/s00392-020-01769-9
_version_ 1783611532851019776
author Cremer, Sebastian
Jakob, Carolin
Berkowitsch, Alexander
Borgmann, Stefan
Pilgram, Lisa
Tometten, Lukas
Classen, Annika
Wille, Kai
Weidlich, Simon
Gruener, Beate
Dimmeler, Stefanie
Massberg, Steffen
Rieg, Siegbert
Zeiher, Andreas M.
author_facet Cremer, Sebastian
Jakob, Carolin
Berkowitsch, Alexander
Borgmann, Stefan
Pilgram, Lisa
Tometten, Lukas
Classen, Annika
Wille, Kai
Weidlich, Simon
Gruener, Beate
Dimmeler, Stefanie
Massberg, Steffen
Rieg, Siegbert
Zeiher, Andreas M.
author_sort Cremer, Sebastian
collection PubMed
description AIMS: SARS-CoV-2 infection is associated with adverse outcomes in patients with cardiovascular disease. Here, we analyzed whether specific biomarkers predict the clinical course of COVID-19 in patients with cardiovascular comorbidities. METHODS AND RESULTS: We enrolled 2147 patients with SARS-CoV-2 infection which were included in the Lean European Open Survey on SARS-CoV‑2 (LEOSS)-registry from March to June 2020. Clinical data and laboratory values were collected and compared between patients with and without cardiovascular comorbidities in different clinical stages of the disease. Predictors for mortality were calculated using multivariate regression analysis. We show that patients with cardiovascular comorbidities display significantly higher markers of myocardial injury and thrombo-inflammatory activation already in the uncomplicated phase of COVID-19. In multivariate analysis, elevated levels of troponin [OR 1.54; (95% CI 1.22–1.96), p < 0.001)], IL-6 [OR 1.69 (95% CI 1.26–2.27), p < 0.013)], and CRP [OR 1.32; (95% CI 1.1–1.58), p < 0.003)] were predictors of mortality in patients with COVID-19. CONCLUSION: Patients with cardiovascular comorbidities show elevated markers of thrombo-inflammatory activation and myocardial injury, which predict mortality, already in the uncomplicated phase of COVID-19. Starting targeted anti-inflammatory therapy and aggressive anticoagulation already in the uncomplicated phase of the disease might improve outcomes after SARS-CoV-2 infection in patients with cardiovascular comorbidities. GRAPHIC ABSTRACT: Elevated markers of thrombo-inflammatory activation predict outcome in patients with cardiovascular comorbidities and COVID-19 disease: insights from the LEOSS registry [Image: see text] ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00392-020-01769-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7674577
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-76745772020-11-19 Elevated markers of thrombo-inflammatory activation predict outcome in patients with cardiovascular comorbidities and COVID-19 disease: insights from the LEOSS registry Cremer, Sebastian Jakob, Carolin Berkowitsch, Alexander Borgmann, Stefan Pilgram, Lisa Tometten, Lukas Classen, Annika Wille, Kai Weidlich, Simon Gruener, Beate Dimmeler, Stefanie Massberg, Steffen Rieg, Siegbert Zeiher, Andreas M. Clin Res Cardiol Original Paper AIMS: SARS-CoV-2 infection is associated with adverse outcomes in patients with cardiovascular disease. Here, we analyzed whether specific biomarkers predict the clinical course of COVID-19 in patients with cardiovascular comorbidities. METHODS AND RESULTS: We enrolled 2147 patients with SARS-CoV-2 infection which were included in the Lean European Open Survey on SARS-CoV‑2 (LEOSS)-registry from March to June 2020. Clinical data and laboratory values were collected and compared between patients with and without cardiovascular comorbidities in different clinical stages of the disease. Predictors for mortality were calculated using multivariate regression analysis. We show that patients with cardiovascular comorbidities display significantly higher markers of myocardial injury and thrombo-inflammatory activation already in the uncomplicated phase of COVID-19. In multivariate analysis, elevated levels of troponin [OR 1.54; (95% CI 1.22–1.96), p < 0.001)], IL-6 [OR 1.69 (95% CI 1.26–2.27), p < 0.013)], and CRP [OR 1.32; (95% CI 1.1–1.58), p < 0.003)] were predictors of mortality in patients with COVID-19. CONCLUSION: Patients with cardiovascular comorbidities show elevated markers of thrombo-inflammatory activation and myocardial injury, which predict mortality, already in the uncomplicated phase of COVID-19. Starting targeted anti-inflammatory therapy and aggressive anticoagulation already in the uncomplicated phase of the disease might improve outcomes after SARS-CoV-2 infection in patients with cardiovascular comorbidities. GRAPHIC ABSTRACT: Elevated markers of thrombo-inflammatory activation predict outcome in patients with cardiovascular comorbidities and COVID-19 disease: insights from the LEOSS registry [Image: see text] ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00392-020-01769-9) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-11-19 2021 /pmc/articles/PMC7674577/ /pubmed/33211155 http://dx.doi.org/10.1007/s00392-020-01769-9 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Paper
Cremer, Sebastian
Jakob, Carolin
Berkowitsch, Alexander
Borgmann, Stefan
Pilgram, Lisa
Tometten, Lukas
Classen, Annika
Wille, Kai
Weidlich, Simon
Gruener, Beate
Dimmeler, Stefanie
Massberg, Steffen
Rieg, Siegbert
Zeiher, Andreas M.
Elevated markers of thrombo-inflammatory activation predict outcome in patients with cardiovascular comorbidities and COVID-19 disease: insights from the LEOSS registry
title Elevated markers of thrombo-inflammatory activation predict outcome in patients with cardiovascular comorbidities and COVID-19 disease: insights from the LEOSS registry
title_full Elevated markers of thrombo-inflammatory activation predict outcome in patients with cardiovascular comorbidities and COVID-19 disease: insights from the LEOSS registry
title_fullStr Elevated markers of thrombo-inflammatory activation predict outcome in patients with cardiovascular comorbidities and COVID-19 disease: insights from the LEOSS registry
title_full_unstemmed Elevated markers of thrombo-inflammatory activation predict outcome in patients with cardiovascular comorbidities and COVID-19 disease: insights from the LEOSS registry
title_short Elevated markers of thrombo-inflammatory activation predict outcome in patients with cardiovascular comorbidities and COVID-19 disease: insights from the LEOSS registry
title_sort elevated markers of thrombo-inflammatory activation predict outcome in patients with cardiovascular comorbidities and covid-19 disease: insights from the leoss registry
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674577/
https://www.ncbi.nlm.nih.gov/pubmed/33211155
http://dx.doi.org/10.1007/s00392-020-01769-9
work_keys_str_mv AT cremersebastian elevatedmarkersofthromboinflammatoryactivationpredictoutcomeinpatientswithcardiovascularcomorbiditiesandcovid19diseaseinsightsfromtheleossregistry
AT jakobcarolin elevatedmarkersofthromboinflammatoryactivationpredictoutcomeinpatientswithcardiovascularcomorbiditiesandcovid19diseaseinsightsfromtheleossregistry
AT berkowitschalexander elevatedmarkersofthromboinflammatoryactivationpredictoutcomeinpatientswithcardiovascularcomorbiditiesandcovid19diseaseinsightsfromtheleossregistry
AT borgmannstefan elevatedmarkersofthromboinflammatoryactivationpredictoutcomeinpatientswithcardiovascularcomorbiditiesandcovid19diseaseinsightsfromtheleossregistry
AT pilgramlisa elevatedmarkersofthromboinflammatoryactivationpredictoutcomeinpatientswithcardiovascularcomorbiditiesandcovid19diseaseinsightsfromtheleossregistry
AT tomettenlukas elevatedmarkersofthromboinflammatoryactivationpredictoutcomeinpatientswithcardiovascularcomorbiditiesandcovid19diseaseinsightsfromtheleossregistry
AT classenannika elevatedmarkersofthromboinflammatoryactivationpredictoutcomeinpatientswithcardiovascularcomorbiditiesandcovid19diseaseinsightsfromtheleossregistry
AT willekai elevatedmarkersofthromboinflammatoryactivationpredictoutcomeinpatientswithcardiovascularcomorbiditiesandcovid19diseaseinsightsfromtheleossregistry
AT weidlichsimon elevatedmarkersofthromboinflammatoryactivationpredictoutcomeinpatientswithcardiovascularcomorbiditiesandcovid19diseaseinsightsfromtheleossregistry
AT gruenerbeate elevatedmarkersofthromboinflammatoryactivationpredictoutcomeinpatientswithcardiovascularcomorbiditiesandcovid19diseaseinsightsfromtheleossregistry
AT dimmelerstefanie elevatedmarkersofthromboinflammatoryactivationpredictoutcomeinpatientswithcardiovascularcomorbiditiesandcovid19diseaseinsightsfromtheleossregistry
AT massbergsteffen elevatedmarkersofthromboinflammatoryactivationpredictoutcomeinpatientswithcardiovascularcomorbiditiesandcovid19diseaseinsightsfromtheleossregistry
AT riegsiegbert elevatedmarkersofthromboinflammatoryactivationpredictoutcomeinpatientswithcardiovascularcomorbiditiesandcovid19diseaseinsightsfromtheleossregistry
AT zeiherandreasm elevatedmarkersofthromboinflammatoryactivationpredictoutcomeinpatientswithcardiovascularcomorbiditiesandcovid19diseaseinsightsfromtheleossregistry
AT elevatedmarkersofthromboinflammatoryactivationpredictoutcomeinpatientswithcardiovascularcomorbiditiesandcovid19diseaseinsightsfromtheleossregistry